NCT04699630 2025-12-22A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerSCRI Development Innovations, LLCPhase 2 Completed121 enrolled
NCT02980341 2024-10-30Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast CancerDaiichi SankyoPhase 1/2 Completed182 enrolled 37 charts